Guardant Health, Inc. (NASDAQ:GH – Get Free Report) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 6,340,000 shares, a decline of 9.4% from the October 31st total of 7,000,000 shares. Based on an average trading volume of 1,800,000 shares, the short-interest ratio is presently 3.5 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GH shares. Citigroup reiterated a “buy” rating and set a $50.00 price target on shares of Guardant Health in a research report on Monday, October 2nd. William Blair reiterated an “outperform” rating on shares of Guardant Health in a research report on Friday, September 8th. Raymond James upgraded Guardant Health from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Monday, November 13th. Sanford C. Bernstein initiated coverage on Guardant Health in a research report on Thursday, September 28th. They issued an “outperform” rating and a $34.00 price objective for the company. Finally, The Goldman Sachs Group lowered their price objective on Guardant Health from $52.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 20th. Fifteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $49.20.

Check Out Our Latest Research Report on GH

Insider Activity at Guardant Health

In related news, insider Kumud Kalia sold 2,125 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $32.59, for a total value of $69,253.75. Following the sale, the insider now directly owns 7,813 shares in the company, valued at approximately $254,625.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 6.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Guardant Health

A number of institutional investors have recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC purchased a new stake in shares of Guardant Health in the second quarter worth $261,000. Oppenheimer Asset Management Inc. grew its stake in shares of Guardant Health by 14.9% in the first quarter. Oppenheimer Asset Management Inc. now owns 12,903 shares of the company’s stock worth $302,000 after acquiring an additional 1,675 shares during the last quarter. Trexquant Investment LP grew its stake in shares of Guardant Health by 151.2% in the second quarter. Trexquant Investment LP now owns 231,593 shares of the company’s stock worth $8,291,000 after acquiring an additional 139,384 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Guardant Health in the second quarter worth $266,000. Finally, Victory Capital Management Inc. grew its stake in shares of Guardant Health by 11.1% in the second quarter. Victory Capital Management Inc. now owns 12,117 shares of the company’s stock worth $434,000 after acquiring an additional 1,213 shares during the last quarter. Institutional investors own 92.65% of the company’s stock.

Guardant Health Trading Up 2.3 %

Shares of Guardant Health stock traded up $0.60 during midday trading on Monday, reaching $26.93. 1,035,932 shares of the company’s stock traded hands, compared to its average volume of 1,870,149. The company has a debt-to-equity ratio of 4.99, a quick ratio of 5.60 and a current ratio of 5.94. The company has a market cap of $3.18 billion, a PE ratio of -6.49 and a beta of 0.90. The stock has a 50 day moving average of $25.94 and a 200-day moving average of $31.77. Guardant Health has a 12 month low of $20.67 and a 12 month high of $53.58.

Guardant Health (NASDAQ:GH – Get Free Report) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.20. The business had revenue of $143.03 million during the quarter, compared to the consensus estimate of $137.25 million. Guardant Health had a negative return on equity of 322.25% and a negative net margin of 80.69%. As a group, equities analysts expect that Guardant Health will post -3.62 EPS for the current fiscal year.

Guardant Health Company Profile (Get Free Report)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Guardant Health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Guardant Health wasn’t on the list.

While Guardant Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

If a company’s CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Original: MarketBeat News Feed: Guardant Health, Inc. (NASDAQ:GH) Short Interest Down 9.4% in November